DE69737867D1 - Zielgerichtete kombinations-immuntherapie für krebs - Google Patents

Zielgerichtete kombinations-immuntherapie für krebs

Info

Publication number
DE69737867D1
DE69737867D1 DE69737867T DE69737867T DE69737867D1 DE 69737867 D1 DE69737867 D1 DE 69737867D1 DE 69737867 T DE69737867 T DE 69737867T DE 69737867 T DE69737867 T DE 69737867T DE 69737867 D1 DE69737867 D1 DE 69737867D1
Authority
DE
Germany
Prior art keywords
therapeutic agent
cancer
conjugate
tumor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737867T
Other languages
English (en)
Other versions
DE69737867T2 (de
Inventor
Gary L Griffiths
Hans J Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of DE69737867D1 publication Critical patent/DE69737867D1/de
Application granted granted Critical
Publication of DE69737867T2 publication Critical patent/DE69737867T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69737867T 1996-05-03 1997-05-02 Zielgerichtete kombinations-immuntherapie für krebs Expired - Lifetime DE69737867T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1701196P 1996-05-03 1996-05-03
US17011P 1996-05-03
PCT/US1997/007395 WO1997041898A1 (en) 1996-05-03 1997-05-02 Targeted combination immunotherapy of cancer

Publications (2)

Publication Number Publication Date
DE69737867D1 true DE69737867D1 (de) 2007-08-09
DE69737867T2 DE69737867T2 (de) 2007-10-18

Family

ID=21780231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737867T Expired - Lifetime DE69737867T2 (de) 1996-05-03 1997-05-02 Zielgerichtete kombinations-immuntherapie für krebs

Country Status (8)

Country Link
US (1) US6077499A (de)
EP (1) EP0954340B1 (de)
JP (1) JP2000510119A (de)
AT (1) ATE365562T1 (de)
AU (1) AU717020B2 (de)
CA (1) CA2253904A1 (de)
DE (1) DE69737867T2 (de)
WO (1) WO1997041898A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228362B1 (en) 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
DE69737867T2 (de) * 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
EP1113819B1 (de) 1998-09-18 2011-02-23 Immunomedics, Inc. Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
EP1351712B1 (de) 2000-06-20 2007-08-01 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
GB0112844D0 (en) * 2001-05-25 2001-07-18 Psimei Pharmaceuticals Plc Neutron capture therapy
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
IL161418A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003209447B8 (en) 2002-03-01 2008-10-23 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
CN102174108B (zh) 2002-03-01 2016-06-29 免疫医疗公司 内在化抗-cd74抗体和使用方法
EP1575507A2 (de) * 2002-04-02 2005-09-21 Scantibodies Laboratory, Inc. Verfahren und vorrichtungen zur behandlung von schweren peripheren bakteriellen infektionen
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2002332087A1 (en) * 2002-10-08 2004-05-04 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
EP1572131B1 (de) 2002-10-08 2016-07-06 Immunomedics, Inc. Antikörper-therapie
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2517730A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US7402385B2 (en) 2003-02-11 2008-07-22 Albert Einstein College Of Medicine Of Yeshiva University Radiolabeled antibodies for treatment of tumors
US8709998B2 (en) * 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
CA2529027C (en) * 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
WO2005086612A2 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
US8551480B2 (en) * 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7732131B2 (en) 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
AU2006218454B2 (en) 2005-03-03 2011-11-17 Immunomedics, Inc. Humanized L243 antibodies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
WO2007042573A2 (en) 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2481427A1 (de) * 2007-03-14 2012-08-01 Endocyte, Inc. Folat-Tubulysin Konjugate
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
NZ590330A (en) * 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
CN103518135B (zh) 2011-03-11 2016-08-17 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX2019001355A (es) 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
ES2637151T3 (es) 2013-02-14 2017-10-11 Innate Pharma Tratamiento del linfoma de células T periféricas
DK3521312T3 (da) 2013-02-20 2021-06-28 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US9561291B2 (en) * 2013-03-15 2017-02-07 Imre Kovesdi Methods of targeting T-cells to tumors
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EA201690780A1 (ru) 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
JP6787789B2 (ja) * 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
CN106456768B (zh) 2014-06-13 2019-12-03 腾博龙公司 含有抗egfr1抗体的缀合物
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
EP3954373A1 (de) 2014-10-07 2022-02-16 Immunomedics, Inc. Neoadjuvante verwendung von antikörper-wirkstoff-konjugaten
ES2941895T3 (es) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III)
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
EP3313443B9 (de) 2015-06-25 2023-10-04 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017003908A1 (en) 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
WO2017189751A1 (en) 2016-04-26 2017-11-02 The University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
AU2017268291B2 (en) 2016-05-19 2022-09-29 Bristol-Myers Squibb Company PET-imaging immunomodulators
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP4141017A4 (de) * 2020-04-24 2024-05-08 The University of Tokyo Duocarmycinderivat und verwendung davon
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4818684A (en) * 1985-09-10 1989-04-04 The Trustees Of Columbia University In The City Of New York Auto-anti-idiotypic monoclonal antibodies to steroid receptors and uses thereof
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
DK0436717T3 (da) * 1989-08-02 2003-05-05 Mitra Medical Technology Ab System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
EP0647450A1 (de) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen
DE69737867T2 (de) * 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs

Also Published As

Publication number Publication date
ATE365562T1 (de) 2007-07-15
US6077499A (en) 2000-06-20
CA2253904A1 (en) 1997-11-13
WO1997041898A1 (en) 1997-11-13
JP2000510119A (ja) 2000-08-08
AU3057297A (en) 1997-11-26
AU717020B2 (en) 2000-03-16
EP0954340A1 (de) 1999-11-10
EP0954340A4 (de) 2003-08-20
EP0954340B1 (de) 2007-06-27
DE69737867T2 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
DE69737867D1 (de) Zielgerichtete kombinations-immuntherapie für krebs
DE60213771D1 (en) Morpholinobildgebung und therapie
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
ES2193143T3 (es) Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
DK0841949T3 (da) Anvendelse af saccharid-konjugater
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
WO2006044643A3 (en) Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
WO2005051315A3 (en) On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
PT920623E (pt) Terapia de captura neutronica do bono utilizando metodo de pre-direccionamento
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2023169896A8 (en) BINDING MOLECULES AGAINST FRα

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BOHMANN & LOOSEN, 80335 MUENCHEN

8364 No opposition during term of opposition